印度过敏性鼻炎患者服用依巴斯汀 10 毫克和苯肾上腺素 10 毫克固定剂量复方制剂的疗效和安全性:一项 4 期多中心研究

M. S, CV Srinivas, Shrinivas Chavan, Ramesh S, Nitin Chandrashekhar Adgaonkar, Krishna Kumar M
{"title":"印度过敏性鼻炎患者服用依巴斯汀 10 毫克和苯肾上腺素 10 毫克固定剂量复方制剂的疗效和安全性:一项 4 期多中心研究","authors":"M. S, CV Srinivas, Shrinivas Chavan, Ramesh S, Nitin Chandrashekhar Adgaonkar, Krishna Kumar M","doi":"10.18231/j.ijirm.2024.003","DOIUrl":null,"url":null,"abstract":"There is a lack of comprehensive studies examining the efficacy and safety of the fixed-dose combination (FDC) of ebastine 10 mg and phenylephrine 10 mg in allergic rhinitis (AR), especially in Indian settings. So, this study aimed to fill the existing research gap by evaluating the efficacy and safety of the FDC ebastine 10 mg and phenylephrine 10 mg in Indian patients with moderate/severe persistent AR.An open-label, non-randomized, single-group, multicentric, phase 4 clinical study included adult patients visiting the outpatient departments of 4 sites across India. All the selected subjects received the FDC once daily in the evening for 5 days. Safety and efficacy of the FDC were evaluated by comparing the Individual Symptoms Score (ISS), Total symptom Score (TSS), and analysing adverse event profiles reported by patients, assessed by the investigator, from baseline to 6 days. The study also assessed the impact of this condition on patients' quality of life using the rhino-conjunctivitis quality of life scale (RQLS). The study included 145 participants with a mean age of 37.17 ± 12.65 years and male-to-female ratio of 1:1.26. Comparison of baseline symptoms with day 6 revealed statistically significant and clinically meaningful improvements in Individual Symptoms Score (ISS). The mean difference in Total Symptom Score (TSS) from baseline to day 6 also showed a substantial improvement of 3.52 ± 1.54 (95% CI: 3.27-3.78; P <0.001). Rhino-conjunctivitis quality of life scale (RQLS) also demonstrated statistically significant improvement from day 1 to day 6 (t = 24.44, P <0.001). Adverse events were effectively managed with the use of readily available over-the-counter medications like antipyretics, analgesics, and/or antacid.The study validated the efficacy and safety of the FDC ebastine 10 mg and phenylephrine 10 mg, in managing AR with good safety profile. The findings underscore the importance of this combination as a viable therapeutic option, with significant improvements in symptom scores and quality of life observed within a short duration.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"6 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of ebastine 10 mg and phenylephrine 10 mg fixed-dose combination in Indian patients with allergic rhinitis: A phase 4 multicentre study\",\"authors\":\"M. S, CV Srinivas, Shrinivas Chavan, Ramesh S, Nitin Chandrashekhar Adgaonkar, Krishna Kumar M\",\"doi\":\"10.18231/j.ijirm.2024.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"There is a lack of comprehensive studies examining the efficacy and safety of the fixed-dose combination (FDC) of ebastine 10 mg and phenylephrine 10 mg in allergic rhinitis (AR), especially in Indian settings. So, this study aimed to fill the existing research gap by evaluating the efficacy and safety of the FDC ebastine 10 mg and phenylephrine 10 mg in Indian patients with moderate/severe persistent AR.An open-label, non-randomized, single-group, multicentric, phase 4 clinical study included adult patients visiting the outpatient departments of 4 sites across India. All the selected subjects received the FDC once daily in the evening for 5 days. Safety and efficacy of the FDC were evaluated by comparing the Individual Symptoms Score (ISS), Total symptom Score (TSS), and analysing adverse event profiles reported by patients, assessed by the investigator, from baseline to 6 days. The study also assessed the impact of this condition on patients' quality of life using the rhino-conjunctivitis quality of life scale (RQLS). The study included 145 participants with a mean age of 37.17 ± 12.65 years and male-to-female ratio of 1:1.26. Comparison of baseline symptoms with day 6 revealed statistically significant and clinically meaningful improvements in Individual Symptoms Score (ISS). The mean difference in Total Symptom Score (TSS) from baseline to day 6 also showed a substantial improvement of 3.52 ± 1.54 (95% CI: 3.27-3.78; P <0.001). Rhino-conjunctivitis quality of life scale (RQLS) also demonstrated statistically significant improvement from day 1 to day 6 (t = 24.44, P <0.001). Adverse events were effectively managed with the use of readily available over-the-counter medications like antipyretics, analgesics, and/or antacid.The study validated the efficacy and safety of the FDC ebastine 10 mg and phenylephrine 10 mg, in managing AR with good safety profile. The findings underscore the importance of this combination as a viable therapeutic option, with significant improvements in symptom scores and quality of life observed within a short duration.\",\"PeriodicalId\":14503,\"journal\":{\"name\":\"IP Indian Journal of Immunology and Respiratory Medicine\",\"volume\":\"6 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IP Indian Journal of Immunology and Respiratory Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18231/j.ijirm.2024.003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IP Indian Journal of Immunology and Respiratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.ijirm.2024.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目前缺乏对依巴斯汀 10 毫克和苯肾上腺素 10 毫克固定剂量复方制剂(FDC)治疗过敏性鼻炎(AR)的疗效和安全性的全面研究,尤其是在印度。因此,本研究旨在通过评估固定剂量复方制剂依巴斯汀 10 毫克和苯肾上腺素 10 毫克在印度中度/重度持续性 AR 患者中的疗效和安全性,填补现有的研究空白。这项开放标签、非随机、单组、多中心、第 4 期临床研究纳入了在印度 4 个地点门诊部就诊的成年患者。所有入选受试者每天傍晚服用一次 FDC,连续服用 5 天。通过比较个体症状评分(ISS)、总症状评分(TSS)以及分析患者报告的不良事件概况,评估 FDC 从基线到 6 天的安全性和疗效。研究还使用犀牛结膜炎生活质量量表(RQLS)评估了这种疾病对患者生活质量的影响。该研究包括 145 名参与者,平均年龄为 37.17 ± 12.65 岁,男女比例为 1:1.26。将基线症状与第 6 天的症状进行比较后发现,个人症状评分(ISS)有显著的统计学意义和临床意义的改善。总症状评分(TSS)从基线到第 6 天的平均差异也显示出大幅改善,为 3.52 ± 1.54 (95% CI: 3.27-3.78; P <0.001)。从第 1 天到第 6 天,犀牛结膜炎生活质量量表(RQLS)也有显著改善(t = 24.44,P <0.001)。通过使用退烧药、镇痛药和/或抗酸剂等现成的非处方药,不良反应得到了有效控制。该研究验证了依巴斯汀 10 毫克和苯肾上腺素 10 毫克 FDC 药物在治疗 AR 方面的有效性和安全性,而且安全性良好。研究结果强调了这种联合用药作为一种可行治疗方案的重要性,在短时间内就能明显改善症状评分和生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Efficacy and safety of ebastine 10 mg and phenylephrine 10 mg fixed-dose combination in Indian patients with allergic rhinitis: A phase 4 multicentre study
There is a lack of comprehensive studies examining the efficacy and safety of the fixed-dose combination (FDC) of ebastine 10 mg and phenylephrine 10 mg in allergic rhinitis (AR), especially in Indian settings. So, this study aimed to fill the existing research gap by evaluating the efficacy and safety of the FDC ebastine 10 mg and phenylephrine 10 mg in Indian patients with moderate/severe persistent AR.An open-label, non-randomized, single-group, multicentric, phase 4 clinical study included adult patients visiting the outpatient departments of 4 sites across India. All the selected subjects received the FDC once daily in the evening for 5 days. Safety and efficacy of the FDC were evaluated by comparing the Individual Symptoms Score (ISS), Total symptom Score (TSS), and analysing adverse event profiles reported by patients, assessed by the investigator, from baseline to 6 days. The study also assessed the impact of this condition on patients' quality of life using the rhino-conjunctivitis quality of life scale (RQLS). The study included 145 participants with a mean age of 37.17 ± 12.65 years and male-to-female ratio of 1:1.26. Comparison of baseline symptoms with day 6 revealed statistically significant and clinically meaningful improvements in Individual Symptoms Score (ISS). The mean difference in Total Symptom Score (TSS) from baseline to day 6 also showed a substantial improvement of 3.52 ± 1.54 (95% CI: 3.27-3.78; P <0.001). Rhino-conjunctivitis quality of life scale (RQLS) also demonstrated statistically significant improvement from day 1 to day 6 (t = 24.44, P <0.001). Adverse events were effectively managed with the use of readily available over-the-counter medications like antipyretics, analgesics, and/or antacid.The study validated the efficacy and safety of the FDC ebastine 10 mg and phenylephrine 10 mg, in managing AR with good safety profile. The findings underscore the importance of this combination as a viable therapeutic option, with significant improvements in symptom scores and quality of life observed within a short duration.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信